Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15837685 | 0.94 | NPC1 (0.42) | MAPTRAB9ANPC1SMN1; SMN2LMNA | |
| SCHEMBL17300424 | 0.94 | ADAMTS5 (0.38) | NPC1 | |
| SCHEMBL17300438 | 0.91 | ALDH1A1 (0.42) | RAB9ANPC1SMN1; SMN2LMNA | |
| SCHEMBL17300432 | 0.91 | SSTR5 (0.40) | RAB9ANPC1 | |
| SCHEMBL17300417 | 0.90 | RXFP1 (0.39) | MAPTRAB9ANPC1MAPK1POLB | |
| SCHEMBL17300419 | 0.90 | NPC1 (0.43) | NPC1 | |
| SCHEMBL17300420 | 0.88 | ALDH1A1 (0.42) | MAPTRAB9ANPC1SMN1; SMN2LMNA | |
| SCHEMBL17300441 | 0.88 | FKBP1A (0.39) | MAPTNPC1TP53POLBCNR2 | |
| SCHEMBL17300440 | 0.87 | EPHX2 (0.42) | SMN1; SMN2LMNA | |
| SCHEMBL17300443 | 0.87 | TRPV1 (0.38) | NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150344498-A1 | Spiroisoxazoline Compounds Having an Activity Potentiating the Activity of an Antibiotic | UNIVERSITE DE DROIT ET DE LA SANTE DE LILLE 2 (FR) | 2015-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344498-A1 | Spiroisoxazoline Compounds Having an Activity Potentiating the Activity of an Antibiotic | NPPA, CFTR, TCF7 | MAPT 4585/4885RAB9A 1044/4885NPC1 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.